Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion from twice-daily Prograf to once-daily LCP-Tacro in stable kidney transplant recipients
2008-003240-11Phase 3Completed
- Sponsor
- Veloxis Pharmaceuticals
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Envarsus XR in kidney transplant immunosuppression and acute rejection (AR) (2 arms), sponsored by Veloxis Pharmaceuticals. Primary endpoint: Primary efficacy endpoint. Started Jan 2009; status: completed.
02
Drugs
Envarsus XR
03
Conditions
kidney transplant immunosuppressionacute rejection (AR)
Beyond the preview
Go deeper on 2008-003240-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003240-11.